A Phase 2b Randomized, Double-blind, Placebo Controlled, Multi-center 12-week Study With an Additional 40-week Follow-up Assessment of Efficacy, Safety and Tolerability of M1095 in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

Trial Profile

A Phase 2b Randomized, Double-blind, Placebo Controlled, Multi-center 12-week Study With an Additional 40-week Follow-up Assessment of Efficacy, Safety and Tolerability of M1095 in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2018

At a glance

  • Drugs ALX 0761 (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Avillion
  • Most Recent Events

    • 16 Feb 2018 According to an Avillion media release, company has received the FDA acceptance for the IND application for this study.
    • 20 Dec 2017 Status changed from planning to not yet recruiting.
    • 04 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top